The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

CropLogic Limited has announced the increase in its industrial hemp trial farm in Oregon, USA.

This increase will see Industrial Hemp move from 150 to 500 acres to further integrate its agronomy, study of crops and soils, and agtech expertise.

It will also allow for its subsidiary, LogicalCropping, to evaluate data for different growing conditions such as soil type, land contours and elevation to optimise crop yields.

CropLogic will use drones, aerial imagery and grower view to apply its agronomy expertise. Total production is estimated to be between 800,000 and 1,100,000 pounds of industrial hemp across the 500 acres.

CropLogic CEO James Cooper-Jones hopes the production will keep increasing.

“We feel the varying growing environments presents an opportunity for CropLogic to further vertically integrate its agronomy and agtech expertise,” he said.

Industrial hemp is used for any industrial (non-drug) use such as fabrics, biodegradable plastics, construction, health food and fuel.

With this trial CropLogic will also release 75,000,000 shares to sophisticated and institutional investors to raise $3 million at $0.04 per share.

It will be undertaken in two phases with the first one to release 42,490,411 shares and raise $1.7 million. The second phase consists of 31,509,589 shares to raise $1.3 million but will be subject to approval at the next general meeting in May 2019.

Please find the announcement here

CLI by the numbers
More From The Market Online

ResMed spikes on robust results and global growth spurt

ResMed shares have climbed following the release of the company's strong Third Quarter FY2024 results.

AML3D secures Australian defence government contract

AML3D signed a contract with the Australian Government Defence Science and Technology Group (DSTG) to supply…

PharmAust CEO’s sayanora triggers stock plunge

Clinical-stage biotechnology company, PharmAust shares plunged 24 per cent so this morning, following the resignation of…

Recce wins safety board approval to dose 4g in R327 UTI infusion trial

Recce Pharma will dose patients with 4g of its R327 intravenous solution to treat UTIs in…